Cell receptor may lead to new 'biomarker' for pancreatic cancer

Jul 01, 2007

A research team led by University of Cincinnati (UC) scientists has identified a potential biological target for pancreatic cancer, a finding they say could help scientists better understand -- and eventually treat -- the disease that kills more than 33,000 people each year.

In laboratory studies led by Andrew Lowy, MD, and Susan Waltz, PhD, the Cincinnati researchers found that a specific cell receptor -- known as the RON receptor tyrosine kinase -- was “overexpressed,” or increased, in pancreatic cancer cells. This, says Waltz, suggests the receptor may also contribute to the disease’s development.

The RON receptor has been found to be active in several cancers -- including breast cancer -- but its role in pancreatic cancer was unknown. This is one of the first studies, published in the July 1, 2007, issue of the journal Cancer Research, to report a link between the RON receptor and pancreatic cancer.

Receptor tyrosine kinases are proteins on the cell surface used to activate specific body functions -- for example cell growth and migration.

“A normal pancreas has very low levels of RON, but our study showed that as tumors progress, so does the level of RON expression in the pancreas cells -- and those overexpressed levels were maintained in ‘metastases,’ the areas that the tumors spread to,” explains Waltz, associate professor and director of the oncology research program in UC’s surgery department.

The team found that the RON receptor was active in 93 percent of what is known as pancreatic intraepithelial neoplasia, an early form of pancreatic duct cancer. In addition, the receptor was present in 79 percent of primary pancreatic cancers and 83 percent of metastatic cancers.

UC researchers believe the RON receptor’s signaling pathways could be a key factor contributing to pancreatic cancer progression. Waltz says if the receptor could be blocked, it would give drug developers a new target for RON-directed therapies that are more effective in treating this deadly disease.

“When cells became invasive,” Waltz said, “we saw higher levels of RON expression that correlated with the aggressive nature of this disease and cancer metastasis. Clearly, this signaling pathway is associated with pancreatic cancer and merits further investigation.”

A relatively rare but difficult disease to treat, pancreatic cancer will affect about 37,000 Americans in 2007. According to the National Cancer Institute, overall survival for the disease is only about 4 percent -- often because the disease spreads before it can be clinically detected.

In the December 2006 issue of Cancer Research, Waltz reported that the RON receptor can also be involved in breast cancer. Based on those earlier findings, she and Lowy wanted to know if the receptor was also expressed in pancreatic cancer -- an aggressive, highly metastatic cancer -- and whether it played a role in disease development.

For the UC study, researchers used the protein HGFL (hepatocyte growth factor-like) to activate the RON receptor. Although stimulating the RON receptor had no effect on pancreatic cell growth, blocking it with targeted antibodies killed more cancer cells than did the standard treatment drug gemcitabine (gem-SITE-uh-bean) alone.

“Our findings suggest that combining antibodies that block the RON receptor and the standard chemotherapy drugs might stop progression of pancreatic cancer more effectively,” says Waltz. “RON could be a promising molecular target for future cancer drug development.”

Waltz stresses, however, that additional preclinical research is needed before RON receptor blockers become available for human testing.

Source: University of Cincinnati

Explore further: DNA alternative to Pap smear sparks medical debate (Update)

add to favorites email to friend print save as pdf

Related Stories

'Vicious cycle' shields, spreads cancer cells

Sep 16, 2013

A "vicious cycle" produces mucus that protects uterine and pancreatic cancer cells and promotes their proliferation, according to researchers at Rice University. The researchers offer hope for a therapeutic ...

Stroma may provide key to better cancer treatment

Oct 26, 2010

A project focusing on the scar tissue surrounding cancer tumours aims to provide new targets for drugs for treating pancreatic cancer, the fifth highest cause of cancer deaths in the UK.

Recommended for you

DNA alternative to Pap smear sparks medical debate (Update)

13 hours ago

A high-tech screening tool for cervical cancer is facing pushback from more than a dozen American patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: ...

User comments : 0

More news stories

Low Vitamin D may not be a culprit in menopause symptoms

A new study from the Women's Health Initiative (WHI) shows no significant connection between vitamin D levels and menopause symptoms. The study was published online today in Menopause, the journal of The North American Menopa ...

Patent talk: Google sharpens contact lens vision

(Phys.org) —A report from Patent Bolt brings us one step closer to what Google may have in mind in developing smart contact lenses. According to the discussion Google is interested in the concept of contact ...

Tech giants look to skies to spread Internet

The shortest path to the Internet for some remote corners of the world may be through the skies. That is the message from US tech giants seeking to spread the online gospel to hard-to-reach regions.

Wireless industry makes anti-theft commitment

A trade group for wireless providers said Tuesday that the biggest mobile device manufacturers and carriers will soon put anti-theft tools on the gadgets to try to deter rampant smartphone theft.